Clinical Trial

A Study to Evaluate the Safety, Tolerability and PK of SK-08

Study acronym: SK-08
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2025 (before its estimated August 7, 2025 completion). Its status may not reflect the trial's current state.
Summary
The trial is conducted in a single-center, randomized, double-blind, placebo-controlled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) ,and pharmacodynamics (PD) characteristics of SK-08 in healthy participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-06.
Trial Details
NCT Number NCT07021157
Lead Sponsor Consun Pharmaceutical Group
Conditions Chronic Kidney Disease(CKD)
Enrollment 48 participants
Start Date 2025-03-09
Primary Completion 2025-08-07 (estimated)
Study Completion 2025-08-07 (estimated)
Updated on ClinicalTrials.gov 2025-06-24